Halt wasn't warranted.
a halt to tell us about Dr. Fahy's previous published research and the EAP. This is a combination of Dec 13, Dec 31, and Sept 16 news releases.
In fact there was supposed to be testing starting in September for this...
Sept 16 - "The EAP for compassionate use is a multi-center, open label study of Bucillamine in hospitalized patients with severe COVID-19 and is being done to complement the Companys Phase 3 COVID-19 study in the U.S. Revive expects to have patients enrolled in the United States this month."